Drug Patents Expiring in 2035

1. Absorica Ld patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711 SUN PHARM Low dose oral pharmaceutical composition of isotretinoin
May, 2035

(10 years from now)

US9700535 SUN PHARM Oral pharmaceutical composition of isotretinoin
Aug, 2035

(10 years from now)




Drugs and Companies using ISOTRETINOIN ingredient

Market Authorisation Date: 05 November, 2019

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

ABSORICA LD family patents

Family Patents

2. Accrufer patent expiration

ACCRUFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 26 July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE

More Information on Dosage

ACCRUFER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Acetadote patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952065 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Feb, 2035

(10 years from now)




Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

4. Adhansia Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 27, 2022
M(M-82) Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

ADHANSIA XR family patents

Family Patents

5. Adrenalin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119876 ENDO OPERATIONS Epinephrine formulations
Mar, 2035

(10 years from now)

US9295657 ENDO OPERATIONS Epinephrine formulations
Mar, 2035

(10 years from now)

US10130592 ENDO OPERATIONS Epinephrine formulations
Mar, 2035

(10 years from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION

How can I launch a generic of ADRENALIN before it's drug patent expiration?
More Information on Dosage

ADRENALIN family patents

Family Patents

6. Airduo Digihaler patent expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(10 years from now)

US9415008

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(10 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(10 years from now)

US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(10 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

7. Airduo Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(10 years from now)

US9415008

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

8. Akynzeo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(10 years from now)

US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(10 years from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(10 years from now)

US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 10 October, 2014

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

AKYNZEO family patents

Family Patents

9. Alecensa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350214 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(10 years from now)

US11433076 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-756) Nov 06, 2020
New Chemical Entity Exclusivity(NCE) Dec 11, 2020
Orphan Drug Exclusivity(ODE-105) Dec 11, 2022
Orphan Drug Exclusivity(ODE) Nov 06, 2024
Orphan Drug Exclusivity(ODE-159) Nov 06, 2024
New Indication(I-947) Apr 18, 2027
Orphan Drug Exclusivity(ODE-477) Apr 18, 2031

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2019

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents

10. Alunbrig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
New Indication(I-847) May 22, 2023
Orphan Drug Exclusivity(ODE) Apr 28, 2024
Orphan Drug Exclusivity(ODE-142) Apr 28, 2024
Orphan Drug Exclusivity(ODE-300) May 22, 2027

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET

More Information on Dosage

ALUNBRIG family patents

Family Patents

11. Amvuttra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(10 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 13, 2027
Orphan Drug Exclusivity(ODE-212) Jun 13, 2029

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION

More Information on Dosage

AMVUTTRA family patents

Family Patents

12. Aponvie patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US11878074 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(10 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US11744800 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(10 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)




Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 16 September, 2022

Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting; A method for preventing post-operative nausea and vomiting; A method for preventing of post-operative nausea ...

Dosage: EMULSION

More Information on Dosage

APONVIE family patents

Family Patents

13. Arakoda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744828 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects
Dec, 2035

(11 years from now)

US10888558 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(11 years from now)

US10342791 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 08, 2021
New Chemical Entity Exclusivity(NCE) Jul 20, 2023

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

NCE-1 date: 20 July, 2022

Market Authorisation Date: 08 August, 2018

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET

More Information on Dosage

ARAKODA family patents

Family Patents

14. Arikayce Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446318 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

US9895385 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

US10751355 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

US10251900 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

US12016873 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part o...

Dosage: SUSPENSION, LIPOSOMAL

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

15. Aristada patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(10 years from now)

US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(10 years from now)

US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(10 years from now)

US11406632 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(10 years from now)

US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ARISTADA family patents

Family Patents

16. Aristada Initio Kit patent expiration

ARISTADA INITIO KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849894 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(10 years from now)

US10688091 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(10 years from now)

US11154552 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(10 years from now)

US10016415 ALKERMES INC Aripiprazole prodrug compositions
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ARISTADA INITIO KIT family patents

Family Patents

17. Armonair Digihaler patent expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(10 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(10 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

18. Armonair Respiclick patent expiration

ARMONAIR RESPICLICK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

19. Augtyro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9714258 BRISTOL Diaryl macrocycles as modulators of protein kinases
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 15, 2028
ODE*(ODE*) Nov 15, 2030
Orphan Drug Exclusivity(ODE-455) Nov 15, 2030
Orphan Drug Exclusivity(ODE-483) Jun 13, 2031
Orphan Drug Exclusivity(ODE-488) Jun 13, 2031

Drugs and Companies using REPOTRECTINIB ingredient

NCE-1 date: 16 November, 2027

Market Authorisation Date: 11 June, 2024

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

AUGTYRO family patents

Family Patents

20. Axumin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION

More Information on Dosage

AXUMIN family patents

Family Patents

21. Bafiertam patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820960 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(10 years from now)

US10105336 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(10 years from now)

US9820961 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(10 years from now)

US9511043 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(10 years from now)

US9566259 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(10 years from now)

US9517209 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(10 years from now)

US9326965 BANNER LIFE SCIENCES Controlled release fumarate esters
Feb, 2035

(10 years from now)

US11903918 BANNER LIFE SCIENCES Fumarate ester dosage forms with enhanced gastrointestinal tolerability
Feb, 2035

(10 years from now)

US9636318 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(10 years from now)

US9814692 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(10 years from now)

US9814691 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(10 years from now)

US10105335 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(10 years from now)

US9636319 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(10 years from now)

US10098863 BANNER LIFE SCIENCES Fumarate esters
Feb, 2035

(10 years from now)

US9326947 BANNER LIFE SCIENCES Controlled release fumarate esters
Feb, 2035

(10 years from now)

US10105337 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(10 years from now)

US10918616 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Jun, 2035

(10 years from now)

US10918617 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Aug, 2035

(10 years from now)

US10918615 BANNER LIFE SCIENCES Fumarate esters
Aug, 2035

(10 years from now)

US10945985 BANNER LIFE SCIENCES Fumarate ester dosage forms
Aug, 2035

(10 years from now)




Drugs and Companies using MONOMETHYL FUMARATE ingredient

Market Authorisation Date: 28 April, 2020

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE

More Information on Dosage

BAFIERTAM family patents

Family Patents

22. Balversa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(10 years from now)

US12037644 JANSSEN BIOTECH Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2024
New Indication(I-930) Jan 19, 2027

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 13 April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations (y373c identified) whose disease has progressed on or after at least one line of...

Dosage: TABLET

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

23. Biktarvy patent expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
Jun, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 18, 2022
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
M(M-82) Feb 24, 2024
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
New Indication(I-942) Feb 23, 2027
M(M-305) Apr 24, 2027
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
Orphan Drug Exclusivity(ODE-468) Feb 23, 2031

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 October, 2021

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

24. Brexafemme patent expiration

BREXAFEMME's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-903) Nov 30, 2025
New Chemical Entity Exclusivity(NCE) Jun 01, 2026
Generating Antibiotic Incentives Now(GAIN) Jun 01, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 01 June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET

More Information on Dosage

BREXAFEMME family patents

Family Patents

25. Bunavail patent expiration

BUNAVAIL IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522188 BDSI Abuse resistant transmucosal drug delivery device
Apr, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 06, 2017

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM

How can I launch a generic of BUNAVAIL before it's drug patent expiration?
More Information on Dosage

BUNAVAIL family patents

Family Patents

26. Calquence patent expiration

CALQUENCE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771696 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022
New Indication(I-817) Nov 21, 2022
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia by orally administering 100 mg of acalabrutinib twice daily in combination with intravenous administration of obinutu...

Dosage: TABLET

More Information on Dosage

CALQUENCE family patents

Family Patents

27. Calquence patent expiration

CALQUENCE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

US11771696 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022
New Indication(I-817) Nov 21, 2022
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with...

Dosage: CAPSULE

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

28. Cinvanti patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US11744800 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(10 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)




Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION

How can I launch a generic of CINVANTI before it's drug patent expiration?
More Information on Dosage

CINVANTI family patents

Family Patents

29. Combogesic Iv patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389416 HIKMA Aqueous formulation comprising paracetamol and ibuprofen
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 17, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient

Market Authorisation Date: 17 October, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

COMBOGESIC IV family patents

Family Patents

30. Cyclophosphamide patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662342 EUGIA PHARMA SPECLTS Formulations of cyclophosphamide liquid concentrate
Jun, 2035

(10 years from now)




Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 25 August, 2021

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of CYCLOPHOSPHAMIDE before it's drug patent expiration?
More Information on Dosage

CYCLOPHOSPHAMIDE family patents

Family Patents

31. Cyclophosphamide patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849916 AVYXA HOLDINGS Stable liquid formulations of cyclophosphamide and its impurities
Jul, 2035

(10 years from now)

US11382923 AVYXA HOLDINGS Stable liquid formulations of cyclophosphamide and processes to prepare the same
Dec, 2035

(11 years from now)




Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 07 June, 2023

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of CYCLOPHOSPHAMIDE before it's drug patent expiration?
More Information on Dosage

CYCLOPHOSPHAMIDE family patents

Family Patents

32. Dayvigo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702529 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)

US11026944 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)

US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 07, 2025
M(M-293) Apr 20, 2026

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 07 April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET

More Information on Dosage

DAYVIGO family patents

Family Patents

33. Definity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)




Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE

More Information on Dosage

DEFINITY family patents

Family Patents

34. Definity Rt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11395856 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)

US10022460 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)




Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE

More Information on Dosage

DEFINITY RT family patents

Family Patents

35. Epidiolex patent expiration

EPIDIOLEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11096905 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11766411 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10137095 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US9956183 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10111840 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10709674 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10709671 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11357741 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10849860 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10709673 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10603288 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11633369 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11446258 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11154516 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10966939 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11311498 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11701330 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US9949937 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US9956186 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US10092525 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US9956185 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11963937 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US9956184 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(10 years from now)

US11065209 JAZZ PHARMS RES Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

US10918608 JAZZ PHARMS RES Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

US11400055 JAZZ PHARMS RES Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 31, 2023
New Chemical Entity Exclusivity(NCE) Sep 28, 2023
Orphan Drug Exclusivity(ODE-216) Sep 28, 2025
M(M-270) Oct 20, 2026
Orphan Drug Exclusivity(ODE-326) Jul 31, 2027
Orphan Drug Exclusivity(ODE-332) Jul 31, 2027

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: 28 September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures in patients with dravet syndrome; Use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome; Use in combination with cl...

Dosage: SOLUTION

How can I launch a generic of EPIDIOLEX before it's drug patent expiration?
More Information on Dosage

EPIDIOLEX family patents

Family Patents

36. Ermeza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345772 MYLAN Liquid levothyroxine formulations
Feb, 2035

(10 years from now)




Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 29 April, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ERMEZA family patents

Family Patents

37. Eskata patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980983 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(10 years from now)

US10493103 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(10 years from now)

US10098910 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(10 years from now)

US10729720 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(10 years from now)

US9675639 ACLARIS Peroxide formulations and methods and applicators for using the same
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 14, 2020

Drugs and Companies using HYDROGEN PEROXIDE ingredient

Market Authorisation Date: 14 December, 2017

Treatment: Treatment of seborrheic keratoses that are raised

Dosage: SOLUTION

More Information on Dosage

ESKATA family patents

Family Patents

38. Evrysdi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 27, 2025
New Chemical Entity Exclusivity(NCE) Aug 07, 2025
M(M-270) Oct 03, 2026
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
Orphan Drug Exclusivity(ODE-400) May 27, 2029

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION

More Information on Dosage

EVRYSDI family patents

Family Patents

39. Evzio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Mar, 2035

(10 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION

More Information on Dosage

EVZIO family patents

Family Patents

40. Evzio (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Mar, 2035

(10 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

41. Exem Foam Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 07, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 08 November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM

More Information on Dosage

EXEM FOAM KIT family patents

Family Patents

42. Exkivity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(10 years from now)

US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2026
Orphan Drug Exclusivity(ODE-374) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: 15 September, 2025

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...

Dosage: CAPSULE

More Information on Dosage

EXKIVITY family patents

Family Patents

43. Fetroja patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-844) Sep 25, 2023
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
Generating Antibiotic Incentives Now(GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: 14 November, 2028

Market Authorisation Date: 14 November, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

FETROJA family patents

Family Patents

44. Fintepla patent expiration

FINTEPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331 UCB INC Control system for control of distribution of medication
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 25, 2023
New Indication(I-887) Mar 25, 2025
Orphan Drug Exclusivity(ODE-312) Jun 25, 2027
Orphan Drug Exclusivity(ODE-393) Mar 25, 2029
Pediatric Exclusivity(PED) Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution

Dosage: SOLUTION

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents

45. Firvanq Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959948 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10959947 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10959949 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US11638692 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10688046 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10959946 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10493028 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)




Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION

How can I launch a generic of FIRVANQ KIT before it's drug patent expiration?
More Information on Dosage

FIRVANQ KIT family patents

Family Patents

46. Fruzaqla patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519142 TAKEDA PHARMS USA Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Sep, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11046674 TAKEDA PHARMS USA Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 08, 2028

Drugs and Companies using FRUQUINTINIB ingredient

NCE-1 date: 09 November, 2027

Market Authorisation Date: 08 November, 2023

Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...

Dosage: CAPSULE

More Information on Dosage

FRUZAQLA family patents

Family Patents

47. Genosyl patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737051 VERO BIOTECH INC Nitrogen dioxide storage device
Oct, 2035

(11 years from now)




Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS

More Information on Dosage

GENOSYL family patents

Family Patents

48. Hetlioz patent expiration

HETLIOZ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12049457 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(10 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(10 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2019
Orphan Drug Exclusivity(ODE) Jan 31, 2021
Orphan Drug Exclusivity(ODE-59) Jan 31, 2021
New Indication(I-850) Dec 01, 2023
Orphan Drug Exclusivity(ODE-330) Dec 01, 2027

Drugs and Companies using TASIMELTEON ingredient

NCE-1 date: 31 January, 2018

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by admi...

Dosage: CAPSULE

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

49. Hetlioz Lq patent expiration

HETLIOZ LQ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12049457 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(10 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(10 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 01, 2023
Orphan Drug Exclusivity(ODE-329) Dec 01, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by admi...

Dosage: SUSPENSION

More Information on Dosage

HETLIOZ LQ family patents

Family Patents

50. Illuccix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031 TELIX Kit for radiolabelling
Jul, 2035

(10 years from now)




Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 17 December, 2021

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Dosage: POWDER

More Information on Dosage

ILLUCCIX family patents

Family Patents

51. Imbruvica patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695350

(Pediatric)

PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(10 years from now)

US9795604

(Pediatric)

PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(10 years from now)

US10463668

(Pediatric)

PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-680) Feb 12, 2017
New Indication(I-689) Jul 28, 2017
New Indication(I-702) Jan 29, 2018
New Chemical Entity Exclusivity(NCE) Nov 13, 2018
New Indication(I-729) Mar 04, 2019
New Dosing Schedule(D-165) May 06, 2019
New Indication(I-736) May 06, 2019
New Indication(I-737) May 06, 2019
New Indication(I-741) Jan 18, 2020
New Indication(I-753) Aug 02, 2020
Orphan Drug Exclusivity(ODE-55) Nov 13, 2020
Orphan Drug Exclusivity(ODE-60) Feb 12, 2021
Orphan Drug Exclusivity(ODE-72) Jul 28, 2021
New Dosing Schedule(D-176) Aug 24, 2021
M(M-236) Jan 25, 2022
Orphan Drug Exclusivity(ODE-86) Jan 29, 2022
Orphan Drug Exclusivity(ODE-109) Mar 04, 2023
Orphan Drug Exclusivity(ODE-117) May 06, 2023
Orphan Drug Exclusivity(ODE-128) Jan 18, 2024
Orphan Drug Exclusivity(ODE) Aug 02, 2024
ODE*(ODE*) Aug 02, 2024
Orphan Drug Exclusivity(ODE-152) Aug 02, 2024
M(M-14) Aug 24, 2025
New Product(NP) Aug 24, 2025
New Patient Population(NPP) Aug 24, 2025
Pediatric Exclusivity(PED) Feb 24, 2026
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 20 December, 2017

Treatment: NA

Dosage: CAPSULE; TABLET; SUSPENSION

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

52. Impoyz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855334 PRIMUS PHARMS Topical compositions comprising a corticosteroid
Mar, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 28, 2020

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: NA

Dosage: CREAM

How can I launch a generic of IMPOYZ before it's drug patent expiration?
More Information on Dosage

IMPOYZ family patents

Family Patents

53. Inlyta patent expiration

INLYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(10 years from now)

US10570202

(Pediatric)

PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Aug, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2017

Drugs and Companies using AXITINIB ingredient

NCE-1 date: 28 January, 2016

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

54. Isturisa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(10 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 06, 2025
Orphan Drug Exclusivity(ODE-286) Mar 06, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 06 March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET

More Information on Dosage

ISTURISA family patents

Family Patents

55. Jublia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478601 BAUSCH Applicator
Apr, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 06, 2019
New Patient Population(NPP) Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

NCE-1 date: 06 June, 2018

Market Authorisation Date: 06 June, 2014

Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION

How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage

JUBLIA family patents

Family Patents

56. Jylamvo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129833 SHORLA Methotrexate formulation
Oct, 2035

(11 years from now)




Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 29 November, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

JYLAMVO family patents

Family Patents

57. Kapspargo Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700530 SPIL Capsule dosage form of metoprolol succinate
Jul, 2035

(10 years from now)

US9504655 SPIL Capsule dosage form of metoprolol succinate
Jul, 2035

(10 years from now)




Drugs and Companies using METOPROLOL SUCCINATE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

KAPSPARGO SPRINKLE family patents

Family Patents

58. Kengreal patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439921 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(10 years from now)

US10039780 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(10 years from now)

US9295687 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(10 years from now)

US9700575 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 22, 2020

Drugs and Companies using CANGRELOR ingredient

NCE-1 date: 23 June, 2019

Market Authorisation Date: 22 June, 2015

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous inf...

Dosage: POWDER

How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage

KENGREAL family patents

Family Patents

59. Kerendia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE49826 BAYER HLTHCARE Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-279) Sep 01, 2025
New Chemical Entity Exclusivity(NCE) Jul 09, 2026

Drugs and Companies using FINERENONE ingredient

NCE-1 date: 09 July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

KERENDIA family patents

Family Patents

60. Kimyrsa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 06, 2019
New Product(NP) Mar 12, 2024
Generating Antibiotic Incentives Now(GAIN) Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: NA

Dosage: POWDER

More Information on Dosage

KIMYRSA family patents

Family Patents

61. Lenvima patent expiration

LENVIMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(10 years from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(10 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-734) May 13, 2019
New Chemical Entity Exclusivity(NCE) Feb 13, 2020
New Indication(I-787) Aug 15, 2021
Orphan Drug Exclusivity(ODE) Feb 13, 2022
Orphan Drug Exclusivity(ODE-87) Feb 13, 2022
New Indication(I-807) Sep 17, 2022
M(M-269) Jul 21, 2024
New Indication(I-868) Aug 10, 2024
M(M-272) Dec 19, 2024
Orphan Drug Exclusivity(ODE-196) Aug 15, 2025
M(M-14) Apr 03, 2027
Pediatric Exclusivity(PED) Oct 03, 2027

Drugs and Companies using LENVATINIB MESYLATE ingredient

NCE-1 date: 03 October, 2026

Market Authorisation Date: 13 February, 2015

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents

62. Licart patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351133 IBSA INST BIO Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Feb, 2035

(10 years from now)

US11344520 IBSA INST BIO Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Feb, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 19, 2021

Drugs and Companies using DICLOFENAC EPOLAMINE ingredient

Market Authorisation Date: 19 December, 2018

Treatment: Method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released

Dosage: SYSTEM

More Information on Dosage

LICART family patents

Family Patents

63. Livdelzi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11596614 CYMABAY Treatment of intrahepatic cholestatic diseases
Mar, 2035

(10 years from now)

US11406611 CYMABAY Treatment of intrahepatic cholestatic diseases
Mar, 2035

(10 years from now)

US10272058 CYMABAY Treatment of intrahepatic cholestatic diseases
Mar, 2035

(10 years from now)

US9486428 CYMABAY Treatment of intrahepatic cholestatic diseases
Mar, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 14, 2029

Drugs and Companies using SELADELPAR LYSINE ingredient

NCE-1 date: 14 August, 2028

Market Authorisation Date: 14 August, 2024

Treatment: Treatment of primary biliary cholangitis (pbc)

Dosage: CAPSULE

More Information on Dosage

LIVDELZI family patents

Family Patents

64. Lokelma patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11738044 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-261) Apr 24, 2023
New Chemical Entity Exclusivity(NCE) May 18, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 18 May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION

How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage

LOKELMA family patents

Family Patents

65. Lonhala Magnair Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376661 SUMITOMO PHARMA AM Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 05, 2020

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

66. Mavyret patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48923 ABBVIE Crystal forms
May, 2035

(10 years from now)

US9321807 ABBVIE Crystal forms
Jun, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48923

(Pediatric)

ABBVIE Crystal forms
Nov, 2035

(11 years from now)

US9321807

(Pediatric)

ABBVIE Crystal forms
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-230) Aug 06, 2021
New Patient Population(NPP) Apr 30, 2022
New Chemical Entity Exclusivity(NCE) Aug 03, 2022
New Dosing Schedule(D-175) Sep 26, 2022
M(M-259) Apr 10, 2023
Orphan Drug Exclusivity(ODE-232) Apr 30, 2026
Orphan Drug Exclusivity(ODE-233) Apr 30, 2026
Orphan Drug Exclusivity(ODE-372) Jun 10, 2028
Pediatric Exclusivity(PED) Dec 10, 2028

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: TABLET; PELLETS

More Information on Dosage

MAVYRET family patents

Family Patents

67. Narcan patent expiration

NARCAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211253 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)

US9629965 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)

US9480644 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)

US10085937 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)

US9707226 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)

US9775838 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)

US9561177 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)

US9468747 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(10 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2017

Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Dosage: SPRAY, METERED

How can I launch a generic of NARCAN before it's drug patent expiration?
More Information on Dosage

NARCAN family patents

Family Patents

68. Nityr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029 CYCLE Pharmaceutical composition
Jan, 2035

(10 years from now)




Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 26 July, 2017

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET

More Information on Dosage

NITYR family patents

Family Patents

69. Obredon patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9549907 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(11 years from now)

US10105324 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(11 years from now)

US9808431 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(11 years from now)




Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 14 November, 2014

Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or i...

Dosage: SOLUTION

More Information on Dosage

OBREDON family patents

Family Patents

70. Ohtuvayre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956171 VERONA PHARMA Liquid inhalation formulation comprising RPL554
Sep, 2035

(10 years from now)

US10945950 VERONA PHARMA Liquid inhalation formulation comprising RPL554
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 26, 2029

Drugs and Companies using ENSIFENTRINE ingredient

NCE-1 date: 26 June, 2028

Market Authorisation Date: 26 June, 2024

Treatment: For the maintenance treatment of chronic obstructive pulmonary disease (copd) in adult patients

Dosage: SUSPENSION

More Information on Dosage

OHTUVAYRE family patents

Family Patents

71. Ojemda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10426782 DAY ONE BIOPHARMS Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation
Jun, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 23, 2029
Orphan Drug Exclusivity(ODE-478) Apr 23, 2031

Drugs and Companies using TOVORAFENIB ingredient

NCE-1 date: 23 April, 2028

Market Authorisation Date: 23 April, 2024

Treatment: NA

Dosage: TABLET; FOR SUSPENSION

More Information on Dosage

OJEMDA family patents

Family Patents

72. Ojjaara patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48285 GLAXOSMITHKLINE N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Jun, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9809559 GLAXOSMITHKLINE (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Jun, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2028
Orphan Drug Exclusivity(ODE-441) Sep 15, 2030

Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 16 September, 2027

Market Authorisation Date: 15 September, 2023

Treatment: For the treatment of intermediate or high-risk myelofibrosis

Dosage: TABLET

More Information on Dosage

OJJAARA family patents

Family Patents

73. Omlonti patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10774072 VISIOX PHARMA Crystal of N-substituted sulfonamide compound
Jun, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48183 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11197849 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11793798 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10765750 VISIOX PHARMA Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10179127 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10702511 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US9415038 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 22 September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION

More Information on Dosage

OMLONTI family patents

Family Patents

74. Ongentys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357468 AMNEAL Medicaments for slowing Parkinson's disease
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 24 April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE

More Information on Dosage

ONGENTYS family patents

Family Patents

75. Onpattro patent expiration

Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 10, 2023
Orphan Drug Exclusivity(ODE-197) Aug 10, 2025
M(M-270) Jan 13, 2026

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION

More Information on Dosage

ONPATTRO family patents

Family Patents

76. Opfolda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10208299 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11753632 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(10 years from now)

US10961522 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE

More Information on Dosage

OPFOLDA family patents

Family Patents

77. Orbactiv patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 06, 2019
Generating Antibiotic Incentives Now(GAIN) Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: NA

Dosage: POWDER

More Information on Dosage

ORBACTIV family patents

Family Patents

78. Orladeyo patent expiration

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US11708333 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 03, 2025
Orphan Drug Exclusivity(ODE-333) Dec 03, 2027

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 03 December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE

More Information on Dosage

ORLADEYO family patents

Family Patents

79. Otiprio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220796 ALK ABELLO Sterilization of ciprofloxacin composition
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 10, 2018
New Indication(I-770) Mar 02, 2021

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: NA

Dosage: INJECTABLE, SUSPENSION

More Information on Dosage

OTIPRIO family patents

Family Patents

80. Oxbryta patent expiration

OXBRYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-281) Nov 25, 2026
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 14 October, 2022

Treatment: Treating sickle cell disease by administering voxelotor and another active agent

Dosage: TABLET

More Information on Dosage

OXBRYTA family patents

Family Patents

81. Oxlumo patent expiration

Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(10 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(10 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(10 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(11 years from now)

US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-901) Oct 06, 2025
New Chemical Entity Exclusivity(NCE) Nov 23, 2025
Orphan Drug Exclusivity(ODE-339) Nov 23, 2027
Orphan Drug Exclusivity(ODE-415) Oct 06, 2029

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 23 November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION

More Information on Dosage

OXLUMO family patents

Family Patents

82. Pemazyre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-899) Aug 26, 2025
Orphan Drug Exclusivity(ODE-292) Apr 17, 2027
Orphan Drug Exclusivity(ODE-404) Aug 26, 2029

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: NA

Dosage: TABLET

More Information on Dosage

PEMAZYRE family patents

Family Patents

83. Pemetrexed patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11147817 SHILPA Pharmaceutical composition of pemetrexed
Mar, 2035

(10 years from now)




Drugs and Companies using PEMETREXED DISODIUM ingredient

Market Authorisation Date: 22 May, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

PEMETREXED family patents

Family Patents

84. Pemfexy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(11 years from now)




Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

PEMFEXY family patents

Family Patents